Applying the Rome Proposal on Exacerbations of Chronic Obstructive Pulmonary Disease: Does Comorbid Chronic Heart Failure Matter?

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2023 Sep 25

PMID 37744733

Authors

Petra Kristina Jacobson

Leili Lind

Hans L Persson

Affiliations

Soon will be listed here.

Abstract

Background: Chronic heart failure (CHF) is a common comorbidity among patients with chronic obstructive pulmonary disease (COPD). Both exacerbations of COPD (ECOPDs) and exacerbations of CHF (ECHFs) display worsening of breathlessness at rest (BaR) and breathlessness at physical activity (BaPA). Comorbid CHF may have an impact on the vital signs assessed, when the Rome proposal (adopted by GOLD 2023) is applied on ECOPDs. Thus, the aim of the present study was to investigate the impact of comorbid CHF on ECOPDs severity, particularly focusing on the influence of comorbid CHF on BaR and BaPA.

Methods: We analysed data on COPD symptoms collected from the telehealth study The eHealth Diary. Patients with COPD (n = 43) and patients with CHF (n = 41) were asked to daily monitor BaR and BaPA, employing a digital pen and scales for BaR and BaPA (from 0 to 10). Twenty-eight patients of the COPD patients presented with comorbid CHF. Totally, 125 exacerbations were analysed.

Results: Exacerbations in the group with COPD patients and comorbid CHF were compared to the group with COPD patients without comorbid CHF and the group with CHF patients. Compared with GOLD 2022, the GOLD 2023 (the Rome proposal) significantly downgraded the ECOPD severity. Comorbid CHF did not interfere significantly on the observed difference. Comorbid CHF did not worsen BaR scores, assessed at inclusion and at the symptom peak of the exacerbations.

Conclusion: In the present study, we find no evidence that comorbid CHF would interfere significantly with the parameters included in the Rome proposal (GOLD 2023). We conclude that the Rome proposal can be safely applied even on COPD patients with very advanced comorbid CHF.

References

Persson H, Sioutas A, Kentson M, Jacobson P, Lundberg P, Dahlqvist Leinhard O . Skeletal Myosteatosis is Associated with Systemic Inflammation and a Loss of Muscle Bioenergetics in Stable COPD. J Inflamm Res. 2022; 15:4367-4384. PMC: 9355337. DOI: 10.2147/JIR.S366204. View

van Eeden S, Leipsic J, Paul Man S, Sin D . The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012; 186(1):11-6. DOI: 10.1164/rccm.201203-0455PP. View

Hedenstrom H, Malmberg P, Fridriksson H . Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1986; 91(3):299-310. DOI: 10.3109/03009738609178670. View

Persson H, Lyth J, Lind L . The Health Diary Telemonitoring and Hospital-Based Home Care Improve Quality of Life Among Elderly Multimorbid COPD and Chronic Heart Failure Subjects. Int J Chron Obstruct Pulmon Dis. 2020; 15:527-541. PMC: 7069558. DOI: 10.2147/COPD.S236192. View

Kentson M, Leanderson P, Jacobson P, Persson H . The influence of disease severity and lifestyle factors on the peak annual 25(OH)D value of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13:1389-1398. PMC: 5927355. DOI: 10.2147/COPD.S156121. View

Althobiani M, Shah A, Khan B, Hurst J . Clinicians' and Researchers' Perspectives on a New Chronic Obstructive Pulmonary Disease Exacerbation Definition: Rome Wasn't Built in a Day. Am J Respir Crit Care Med. 2023; 207(8):1095-1097. PMC: 10112434. DOI: 10.1164/rccm.202210-1949LE. View

Ellingsen J, Johansson G, Larsson K, Lisspers K, Malinovschi A, Stallberg B . Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2020; 15:235-245. PMC: 7006848. DOI: 10.2147/COPD.S231296. View

Malinovschi A, Zhou X, Bake B, Bergstrom G, Blomberg A, Brisman J . Assessment of Global Lung Function Initiative (GLI) reference equations for diffusing capacity in relation to respiratory burden in the Swedish CArdioPulmonary bioImage Study (SCAPIS). Eur Respir J. 2020; 56(2). DOI: 10.1183/13993003.01995-2019. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

10.

Persson H, Richardson D . Iron-binding drugs targeted to lysosomes: a potential strategy to treat inflammatory lung disorders. Expert Opin Investig Drugs. 2005; 14(8):997-1008. DOI: 10.1517/13543784.14.8.997. View

11.

Jacobson P, Lind L, Persson H . The Exacerbation of Chronic Obstructive Pulmonary Disease: Which Symptom is Most Important to Monitor?. Int J Chron Obstruct Pulmon Dis. 2023; 18:1533-1541. PMC: 10364823. DOI: 10.2147/COPD.S417735. View

12.

Persson H, Sioutas A, Jacobson P, Vainikka L . Human Lung Macrophages Challenged to Oxidants ex vivo: Lysosomal Membrane Sensitization is Associated with Inflammation and Chronic Airflow Limitation. J Inflamm Res. 2020; 13:925-932. PMC: 7678820. DOI: 10.2147/JIR.S280419. View

13.

Persson H, Lyth J, Wirehn A, Lind L . Elderly patients with COPD require more health care than elderly heart failure patients do in a hospital-based home care setting. Int J Chron Obstruct Pulmon Dis. 2019; 14:1569-1581. PMC: 6642647. DOI: 10.2147/COPD.S207621. View

14.

Lyth J, Lind L, Persson H, Wirehn A . Can a telemonitoring system lead to decreased hospitalization in elderly patients?. J Telemed Telecare. 2019; 27(1):46-53. DOI: 10.1177/1357633X19858178. View

15.

Reumkens C, Endres A, Simons S, Savelkoul P, Sprooten R, Franssen F . Application of the Rome severity classification of COPD exacerbations in a real-world cohort of hospitalised patients. ERJ Open Res. 2023; 9(3). PMC: 10204729. DOI: 10.1183/23120541.00569-2022. View

16.

Sioutas A, Vainikka L, Kentson M, Dam-Larsen S, Wennerstrom U, Jacobson P . Oxidant-induced autophagy and ferritin degradation contribute to epithelial-mesenchymal transition through lysosomal iron. J Inflamm Res. 2017; 10:29-39. PMC: 5378460. DOI: 10.2147/JIR.S128292. View

17.

Giezeman M, Sundh J, Athlin A, Lisspers K, Stallberg B, Janson C . Comorbid Heart Disease in Patients with COPD is Associated with Increased Hospitalization and Mortality - A 15-Year Follow-Up. Int J Chron Obstruct Pulmon Dis. 2023; 18:11-21. PMC: 9838124. DOI: 10.2147/COPD.S378979. View

18.

Giezeman M, Hasselgren M, Lisspers K, Stallberg B, Montgomery S, Janson C . Influence of comorbid heart disease on dyspnea and health status in patients with COPD - a cohort study. Int J Chron Obstruct Pulmon Dis. 2018; 13:3857-3865. PMC: 6276822. DOI: 10.2147/COPD.S175641. View

19.

Ponikowski P, Voors A, Anker S, Bueno H, Cleland J, Coats A . 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special.... Eur J Heart Fail. 2016; 18(8):891-975. DOI: 10.1002/ejhf.592. View

20.

Chen W, Thomas J, Sadatsafavi M, FitzGerald J . Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3(8):631-9. DOI: 10.1016/S2213-2600(15)00241-6. View